



Clinical trial results:

A prospective randomised controlled trial comparing the use of open label pentoxifylline and tocopherol versus current standard of care for the prevention of fibrosis related outcomes in irradiated head and neck oncology patients (Feasibility Study)

Summary

| | |
|--------------------------|------------------|
| EudraCT number | 2018-001153-27 |
| Trial protocol | GB |
| Global end of trial date | 30 November 2023 |

Results information

| | |
|-----------------------------------|---|
| Result version number | v1 (current) |
| This version publication date | 23 August 2025 |
| First version publication date | 23 August 2025 |
| Summary attachment (see zip file) | PENVE CSR EudraCT Results Upload 13Jun25 (PENVE CSR EudraCT Results Upload 13Jun25.pdf) |

Trial information

Trial identification

| | |
|-----------------------|-------|
| Sponsor protocol code | PenVe |
|-----------------------|-------|

Additional study identifiers

| | |
|------------------------------------|----------------|
| ISRCTN number | ISRCTN74484952 |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Guy's and St Thomas NHS Foundation Trust |
| Sponsor organisation address | Great Maze Pond, London, United Kingdom, SE1 9RT |
| Public contact | Mr Vinod Patel, , Guy's and St Thomas' NHS Foundation Trust, 44 0207188 3885, vinod.patel@gstt.nhs.uk |
| Scientific contact | Mr Vinod Patel, , Guy's and St Thomas' NHS Foundation Trust, 44 0207188 3885, vinod.patel@gstt.nhs.uk |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 28 November 2023 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 02 August 2023 |
| Global end of trial reached? | Yes |
| Global end of trial date | 30 November 2023 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To assess the feasibility of a randomised controlled trial of pentoxifylline in combination with vitamin E (PVe) for the prevention of radiation induced fibrosis outcomes in head and neck radiotherapy patients compared to best standard of care.

- To assess patient's preference for pentoxifylline and vitamin E formulation, in a tablet vs liquid format (Intervention group only)
- To assess patient's subsequent side effects related to the pentoxifylline and vitamin E (Intervention group only)
- To assess the recruitment into the trial
- To assess retention of the participants in the trial
- To assess the participation in the trial follow up visits and phone calls
- To assess patient adherence to pentoxifylline and Vitamin E (Intervention group only)
- To assess the acceptability to participants of the outcome measurement tools

Protection of trial subjects:

Participants have the right to withdraw from the study at any time for any reason. The investigator also has the right to withdraw patients from the study drug in the event of inter-current illness, AEs, SAE's, SUSAR's, protocol violations, cure, administrative reasons or other reasons. Participants who develop ORN will be withdrawn from the study. Reaching this endpoint would mean that the treatment did not work and would be of no benefit to continue. Outcome measures would also not be comparable to participants who did not develop ORN. It is understood by all concerned that an excessive rate of withdrawals can render the study un-interpretable; therefore, unnecessary withdrawal of patients should be avoided. Should a patient

decide to withdraw from the study, all efforts will be made to report the reason for withdrawal as thoroughly as possible. Should a patient withdraw from study drug only, efforts will be made to continue to retain and obtain follow-up data, with the permission of the patient.

Participants who wish to withdraw from trial medication (IMP) will be asked to confirm whether they are still willing to provide the following:

- Trial specific data at visits attended
- Data collected as per routine clinical practice at visits attended

Background therapy: -

Evidence for comparator: -

| | |
|---|----------------|
| Actual start date of recruitment | 05 August 2019 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | United Kingdom: 29 |
| Worldwide total number of subjects | 29 |
| EEA total number of subjects | 29 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 22 |
| From 65 to 84 years | 7 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details: -

Pre-assignment period milestones

| | |
|----------------------------|-------------------|
| Number of subjects started | 54 ^[1] |
|----------------------------|-------------------|

| | |
|------------------------------|----|
| Number of subjects completed | 29 |
|------------------------------|----|

Pre-assignment subject non-completion reasons

| | |
|----------------------------|--------------------|
| Reason: Number of subjects | Screen Failure: 25 |
|----------------------------|--------------------|

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: We do not count screening participants as enrolled

Period 1

| | |
|----------------|--------------------------------|
| Period 1 title | Overall trial (overall period) |
|----------------|--------------------------------|

| | |
|------------------------------|-----|
| Is this the baseline period? | Yes |
|------------------------------|-----|

| | |
|-------------------|-------------------------|
| Allocation method | Randomised - controlled |
|-------------------|-------------------------|

| | |
|---------------|-------------|
| Blinding used | Not blinded |
|---------------|-------------|

Blinding implementation details:

open labelled trial investigating outcomes following the prophylactic use of pentoxifylline and tocopherol in irradiated head and neck oncology patients.

Arms

| | |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

| | |
|-----------|---------------------|
| Arm title | Investigational Arm |
|-----------|---------------------|

Arm description: -

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|-----------------------------|
| Investigational medicinal product name | Pentoxifylline & Tocopheryl |
|--|-----------------------------|

| | |
|--|--|
| Investigational medicinal product code | |
|--|--|

| | |
|------------|--|
| Other name | |
|------------|--|

| | |
|----------------------|--------------------------------------|
| Pharmaceutical forms | Modified-release tablet, Oral liquid |
|----------------------|--------------------------------------|

| | |
|--------------------------|----------|
| Routes of administration | Oral use |
|--------------------------|----------|

Dosage and administration details:

-Pentoxifylline dose: 400mg (liquid or tablet formulation) TWICE a day.

-Vitamin E (alpha-tocopheryl) dose: 1000 IU (liquid or tablet formulation) ONCE a day.

| | |
|-----------|---------|
| Arm title | Control |
|-----------|---------|

Arm description: -

| | |
|----------|-----------------|
| Arm type | No intervention |
|----------|-----------------|

No investigational medicinal product assigned in this arm

| Number of subjects in period 1 | Investigational Arm | Control |
|---------------------------------------|---------------------|---------|
| Started | 22 | 7 |
| Completed | 16 | 6 |
| Not completed | 6 | 1 |
| Treatment failure | 1 | - |
| Lost to follow-up | 3 | - |
| No longer wished to take part | 1 | 1 |
| Had recurrence of cancer | 1 | - |

Baseline characteristics

Reporting groups

| | |
|--------------------------------|---------------------|
| Reporting group title | Investigational Arm |
| Reporting group description: - | |
| Reporting group title | Control |
| Reporting group description: - | |

| Reporting group values | Investigational Arm | Control | Total |
|---|---------------------|---------|-------|
| Number of subjects | 22 | 7 | 29 |
| Age categorical Units: Subjects | | | |
| In utero | | | 0 |
| Preterm newborn infants (gestational age < 37 wks) | | | 0 |
| Newborns (0-27 days) | | | 0 |
| Infants and toddlers (28 days-23 months) | | | 0 |
| Children (2-11 years) | | | 0 |
| Adolescents (12-17 years) | | | 0 |
| Adults (18-64 years) | | | 0 |
| From 65-84 years | | | 0 |
| 85 years and over | | | 0 |
| Age continuous Units: years | | | |
| arithmetic mean | 59.3 | 56.9 | |
| standard deviation | ± 8.60 | ± 6.64 | - |
| Gender categorical Units: Subjects | | | |
| Female | 4 | 1 | 5 |
| Male | 18 | 6 | 24 |

End points

End points reporting groups

| | |
|--------------------------------|---------------------|
| Reporting group title | Investigational Arm |
| Reporting group description: - | |
| Reporting group title | Control |
| Reporting group description: - | |

Primary: Primary outcome 1: Requested formulation change for Pentoxifylline or Vitamin E

| | |
|------------------------|--|
| End point title | Primary outcome 1: Requested formulation change for Pentoxifylline or Vitamin E ^[1] |
| End point description: | |
| End point type | Primary |
| End point timeframe: | |
| Day 1 to Month 6 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Please see uploaded report

| End point values | Investigational Arm | Control | | |
|--|---------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 22 | 7 | | |
| Units: 29 | | | | |
| Yes | 0 | 0 | | |
| No, never requested to change formulation during | 22 | 0 | | |
| No, participant is not in intervention arm | 0 | 5 | | |
| Not applicable | 0 | 2 | | |
| Missing | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Primary Outcome 5a: Participation in the trial follow-up visits (Intent-to-treat population)

| | |
|--|---|
| End point title | Primary Outcome 5a: Participation in the trial follow-up visits (Intent-to-treat population) ^[2] |
| End point description: | |
| Participation in the trial follow-up visits (Intent-to-treat population) | |
| End point type | Primary |

End point timeframe:

Baseline to Month 6

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Please see uploaded report

| End point values | Investigational Arm | Control | | |
|-----------------------------|---------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 22 | 7 | | |
| Units: 29 | | | | |
| Visit 1 (Absent) | 0 | 0 | | |
| Visit 1 (Present) | 22 | 7 | | |
| Visit 2 (Absent) | 0 | 0 | | |
| Visit 2 (Present) | 22 | 7 | | |
| Visit 3 (Absent) | 0 | 0 | | |
| Visit 3 (Present) | 22 | 7 | | |
| Visit 4 (Absent) | 1 | 1 | | |
| Visit 4 (Present) | 21 | 6 | | |
| Visit 5 (Absent) | 3 | 1 | | |
| Visit 5 (Present) | 19 | 6 | | |
| Visit 6 (Absent) | 0 | 0 | | |
| Visit 6 (Present) | 22 | 7 | | |

Statistical analyses

No statistical analyses for this end point

Primary: Primary Outcome 5b: Participation in trial follow-up visits (Intent-to-treat population) - phone call

| | |
|-----------------|---|
| End point title | Primary Outcome 5b: Participation in trial follow-up visits (Intent-to-treat population) - phone call ^[3] ^[4] |
|-----------------|---|

End point description:

Participation in trial follow-up visits by phone call (Intent-to-treat population)

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline to Month 6

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Please see uploaded report

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint only concerned the active intervention arm. Please see uploaded report

| End point values | Investigational Arm | | | |
|---|---------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 22 | | | |
| Units: 22 | | | | |
| Day 1 Team contacted participant - Successful | 19 | | | |
| Day 1 Team contacted participant - Not Successful | 0 | | | |
| Day 1 Participant contacted study team | 0 | | | |
| Day 1 Not applicable | 0 | | | |
| Day 1 Missing | 3 | | | |
| Day 2 Team contacted participant - Successful | 18 | | | |
| Day 2 Team contacted participant - Not Successful | 1 | | | |
| Day 2 Participant contacted study team | 0 | | | |
| Day 2 Not applicable | 0 | | | |
| Day 2 Missing | 3 | | | |
| Day 3 Team contacted participant - Successful | 19 | | | |
| Day 3 Team contacted participant - Not Successful | 0 | | | |
| Day 3 Participant contacted study team | 0 | | | |
| Day 3 Not applicable | 0 | | | |
| Day 3 Missing | 3 | | | |
| Day 4 Team contacted participant - Successful | 19 | | | |
| Day 4 Team contacted participant - Not Successful | 0 | | | |
| Day 4 Participant contacted study team | 0 | | | |
| Day 4 Not applicable | 0 | | | |
| Day 4 Missing | 3 | | | |
| Day 5 Team contacted participant - Successful | 19 | | | |
| Day 5 Team contacted participant - Not Successful | 0 | | | |
| Day 5 Participant contacted study team | 0 | | | |
| Day 5 Not applicable | 0 | | | |
| Day 5 Missing | 3 | | | |
| Day 6 Team contacted participant - Successful | 17 | | | |
| Day 6 Team contacted participant - Not Successful | 2 | | | |
| Day 6 Participant contacted study team | 0 | | | |
| Day 6 Not applicable | 0 | | | |
| Day 6 Missing | 3 | | | |
| Day 7 Team contacted participant - Successful | 19 | | | |
| Day 7 Team contacted participant - Not Successful | 0 | | | |
| Day 7 Participant contacted study team | 0 | | | |
| Day 7 Not applicable | 0 | | | |
| Day 7 Missing | 3 | | | |
| Day 8 Team contacted participant - Successful | 18 | | | |

| | | | | |
|--|----|--|--|--|
| Day 8 Team contacted participant - Not Successful | 1 | | | |
| Day 8 Participant contacted study team | 0 | | | |
| Day 8 Not applicable | 0 | | | |
| Day 8 Missing | 3 | | | |
| Day 9 Team contacted participant - Successful | 17 | | | |
| Day 9 Team contacted participant - Not Successful | 2 | | | |
| Day 9 Participant contacted study team | 0 | | | |
| Day 9 Not applicable | 0 | | | |
| Day 9 Missing | 3 | | | |
| Day 10 Team contacted participant - Successful | 19 | | | |
| Day 10 Team contacted participant - Not Successful | 0 | | | |
| Day 10 Participant contacted study team | 0 | | | |
| Day 10 Not applicable | 0 | | | |
| Day 10 Missing | 3 | | | |
| Day 11 Team contacted participant - Successful | 17 | | | |
| Day 11 Team contacted participant - Not Successful | 1 | | | |
| Day 11 Participant contacted study team | 0 | | | |
| Day 11 Not applicable | 0 | | | |
| Day 11 Missing | 4 | | | |
| Day 12 Team contacted participant - Successful | 16 | | | |
| Day 12 Team contacted participant - Not Successful | 2 | | | |
| Day 12 Participant contacted study team | 0 | | | |
| Day 12 Not applicable | 0 | | | |
| Day 12 Missing | 4 | | | |
| Day 13 Team contacted participant - Successful | 17 | | | |
| Day 13 Team contacted participant - Not Successful | 1 | | | |
| Day 13 Participant contacted study team | 0 | | | |
| Day 13 Not applicable | 0 | | | |
| Day 13 Missing | 4 | | | |
| Day 14 Team contacted participant - Successful | 17 | | | |
| Day 14 Team contacted participant - Not Successful | 1 | | | |
| Day 14 Participant contacted study team | 0 | | | |
| Day 14 Not applicable | 0 | | | |
| Day 14 Missing | 4 | | | |
| Week 5 Team contacted participant - Successful | 15 | | | |
| Week 5 Team contacted participant - Not Successful | 3 | | | |
| Week 5 Participant contacted study team | 0 | | | |
| Week 5 Not applicable | 0 | | | |
| Week 5 Missing | 4 | | | |
| Week 8 Team contacted participant - Successful | 14 | | | |

| | | | | |
|---|----|--|--|--|
| Week 8 Team contacted participant - Not Successful | 2 | | | |
| Week 8 Participant contacted study team | 0 | | | |
| Week 8 Not applicable | 0 | | | |
| Week 8 Missing | 6 | | | |
| Week 11 Team contacted participant Successful | 14 | | | |
| Week 11 Team contacted participant Not Successful | 2 | | | |
| Week 11 Participant contacted study team | 0 | | | |
| Week 11 Not applicable | 0 | | | |
| Week 11 Missing | 6 | | | |
| Week 14 Team contacted participant Successful | 11 | | | |
| Week 14 Team contacted participant Not Successful | 5 | | | |
| Week 14 Participant contacted study team | 0 | | | |
| Week 14 Not applicable | 0 | | | |
| Week 14 Missing | 6 | | | |
| Week 17 Team contacted participant Successful | 10 | | | |
| Week 17 Team contacted participant Not Successful | 3 | | | |
| Week 17 Participant contacted study team | 0 | | | |
| Week 17 Not applicable | 0 | | | |
| Week 17 Missing | 9 | | | |
| Week 20 Team contacted participant Successful | 10 | | | |
| Week 20 Team contacted participant Not Successful | 3 | | | |
| Week 20 Participant contacted study team | 0 | | | |
| Week 20 Not applicable | 0 | | | |
| Week 20 Missing | 9 | | | |
| Week 23 Team contacted participant Successful | 9 | | | |
| Week 23 Team contacted participant Not Successful | 2 | | | |
| Week 23 Participant contacted study team | 0 | | | |
| Week 23 Not applicable | 0 | | | |
| Week 23 Missing | 11 | | | |
| Week 26 Team contacted participant Successful | 5 | | | |
| Week 26 Team contacted participant Not Successful | 2 | | | |
| Week 26 Participant contacted study team | 0 | | | |
| Week 26 Not applicable | 0 | | | |
| Week 26 Missing | 15 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Primary Outcome 6: Patient adherence as measured by blood vitamin E levels at Baseline, Month 3 and Month 6 time points (Intent-to-Treat Population)

| | |
|-----------------|---|
| End point title | Primary Outcome 6: Patient adherence as measured by blood vitamin E levels at Baseline, Month 3 and Month 6 time points (Intent-to-Treat Population) ^[5] |
|-----------------|---|

End point description:

Patient adherence as measured by blood vitamin E levels at Baseline, Month 3 and Month 6 time points (Intent-to-Treat Population)

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Day 1 to Month 6

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Please see uploaded report

| End point values | Investigational Arm | Control | | |
|--------------------------------------|---------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 22 | 7 | | |
| Units: ng/mL | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 35.2 (± 10.6) | 29.6 (± 7.34) | | |
| Month 3 | 91.8 (± 184) | 31.8 (± 5.36) | | |
| Month 6 | 55.2 (± 22.3) | 31.6 (± 8.41) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Primary outcome 6: Patient adherence to IMP measured by self-report (only intervention arm of Intent-to-Treat Population)

| | |
|-----------------|---|
| End point title | Primary outcome 6: Patient adherence to IMP measured by self-report (only intervention arm of Intent-to-Treat Population) ^{[6][7]} |
|-----------------|---|

End point description:

Patient adherence to IMP measured by self-report (only intervention arm of Intent-to-Treat Population)

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Day 1 to Month 6

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Please see uploaded report

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint only concerned the active intervention arm. Please see uploaded report

| End point values | Investigational Arm | | | |
|---|---------------------|--|--|--|
| Subject group type | Reporting group | | | |
| Number of subjects analysed | 22 | | | |
| Units: 100 | | | | |
| Number of missed Vitamin E doses (%) | 10 | | | |
| Number of missed Pentoxifylline doses (%) | 25 | | | |

Statistical analyses

No statistical analyses for this end point

Primary: Primary Outcome 7: Acceptability of questionnaires as measures by the number (%) of Questionnaires Completed by Participants by Treatment (Intent-to-Treat Population)

| | |
|-----------------|---|
| End point title | Primary Outcome 7: Acceptability of questionnaires as measures by the number (%) of Questionnaires Completed by Participants by Treatment (Intent-to-Treat Population) ^[8] |
|-----------------|---|

End point description:

Acceptability of questionnaires as measures by the number (%) of Questionnaires Completed by Participants by Treatment (Intent-to-Treat Population)

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Baseline to month 6

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Please see uploaded report

| End point values | Investigational Arm | Control | | |
|------------------------------|---------------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 22 | 7 | | |
| Units: 29 | | | | |
| Baseline (UW-QOL) Complete | 18 | 5 | | |
| Baseline (UW-QOL) Incomplete | 4 | 2 | | |
| Month 3 (UW-QOL) Complete | 16 | 5 | | |
| Month 3 (UW-QOL) Incomplete | 6 | 2 | | |
| Month 6 (UW-QOL) Complete | 12 | 5 | | |
| Month 6 (UW-QOL) Incomplete | 10 | 2 | | |
| Baseline (SSQ) Complete | 20 | 7 | | |
| Baseline (SSQ) Incomplete | 2 | 0 | | |
| Month 3 (SSQ) Complete | 13 | 6 | | |
| Month 3 (SSQ) Incomplete | 9 | 1 | | |
| Month 6 (SSQ) Complete | 8 | 6 | | |
| Month 6 (SSQ) Incomplete | 14 | 1 | | |

Statistical analyses

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 to month 6 visit

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 22.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|----------------------------|
| Reporting group title | Pentoxifylline & Vitamin E |
|-----------------------|----------------------------|

Reporting group description: -

| | |
|-----------------------|--------|
| Reporting group title | Contol |
|-----------------------|--------|

Reporting group description: -

| Serious adverse events | Pentoxifylline & Vitamin E | Contol | |
|--|----------------------------|---------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| General disorders and administration site conditions | | | |
| High Temperature | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 0 %

| Non-serious adverse events | Pentoxifylline & Vitamin E | Contol | |
|---|----------------------------|----------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 11 / 22 (50.00%) | 1 / 7 (14.29%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| Recurrent head and neck cancer | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Cardiac disorders | | | |

| | | | |
|--|----------------------|---------------------|--|
| Atrial flutter subjects affected / exposed occurrences (all) | 1 / 22 (4.55%) 1 | 0 / 7 (0.00%) 0 | |
| Surgical and medical procedures Radiography to replace NG tube subjects affected / exposed occurrences (all) | 1 / 22 (4.55%) 1 | 0 / 7 (0.00%) 0 | |
| General disorders and administration site conditions Muscle Pain subjects affected / exposed occurrences (all) | 1 / 22 (4.55%) 1 | 0 / 7 (0.00%) 0 | |
| Dizziness subjects affected / exposed occurrences (all) | 3 / 22 (13.64%) 6 | 0 / 7 (0.00%) 0 | |
| Dry mouth subjects affected / exposed occurrences (all) | 3 / 22 (13.64%) 3 | 0 / 7 (0.00%) 0 | |
| Pyrexia subjects affected / exposed occurrences (all) | 1 / 22 (4.55%) 1 | 0 / 7 (0.00%) 0 | |
| Saliva decreased subjects affected / exposed occurrences (all) | 0 / 22 (0.00%) 0 | 1 / 7 (14.29%) 1 | |
| NG tube fell out subjects affected / exposed occurrences (all) | 1 / 22 (4.55%) 1 | 0 / 7 (0.00%) 0 | |
| Purulent phlegm subjects affected / exposed occurrences (all) | 1 / 22 (4.55%) 1 | 0 / 7 (0.00%) 0 | |
| Tremor subjects affected / exposed occurrences (all) | 1 / 22 (4.55%) 1 | 0 / 7 (0.00%) 0 | |
| Dyspnoea subjects affected / exposed occurrences (all) | 1 / 22 (4.55%) 1 | 0 / 7 (0.00%) 0 | |
| Pain in jaw | | | |

| | | | |
|-----------------------------|-----------------|---------------|--|
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Tongue pain | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Mouth ulceration | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Headache | | | |
| subjects affected / exposed | 3 / 22 (13.64%) | 0 / 7 (0.00%) | |
| occurrences (all) | 6 | 0 | |
| Migraine | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Paraesthesia (leg) | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Dysphagia | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Gastrointestinal disorders | | | |
| Gastric Irritation | | | |
| subjects affected / exposed | 3 / 22 (13.64%) | 0 / 7 (0.00%) | |
| occurrences (all) | 4 | 0 | |
| Vomiting | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 10 | 0 | |
| Constipation | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Abdominal pain | | | |
| subjects affected / exposed | 2 / 22 (9.09%) | 0 / 7 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 22 (9.09%) | 0 / 7 (0.00%) | |
| occurrences (all) | 2 | 0 | |

| | | | |
|---|----------------|---------------|--|
| Nausea | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Oesophagitis | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Abdominal noises | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Pneumonia | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Throat irritation | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| COVID | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Cough | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Dry throat | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Psychiatric disorders | | | |
| Depression | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Metabolism and nutrition disorders | | | |
| Hypothyroidism | | | |
| subjects affected / exposed | 1 / 22 (4.55%) | 0 / 7 (0.00%) | |
| occurrences (all) | 1 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---------------|----------------|
| 10 June 2020 | SA protocol V2 |
| 01 April 2021 | IMPD v4.0 |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|---------------|--------------|-----------------|
| 18 March 2020 | COVID | 05 October 2020 |

Notes:

Limitations and caveats

None reported